270 related articles for article (PubMed ID: 26317265)
1. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
2. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
3. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
Verma SK
Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
[TBL] [Abstract][Full Text] [Related]
6. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
9. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
11. EZH2 is highly expressed in pituitary adenomas and associated with proliferation.
Schult D; Hölsken A; Siegel S; Buchfelder M; Fahlbusch R; Kreitschmann-Andermahr I; Buslei R
Sci Rep; 2015 Nov; 5():16965. PubMed ID: 26593398
[TBL] [Abstract][Full Text] [Related]
12. Targeting EZH2 for cancer therapy: progress and perspective.
Han Li C; Chen Y
Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
[TBL] [Abstract][Full Text] [Related]
13. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
14. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
15. A Potential Epigenetic Therapy for NSCLC.
Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
[TBL] [Abstract][Full Text] [Related]
16. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
17. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2.
Dasgupta M; Dermawan JK; Willard B; Stark GR
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):3985-90. PubMed ID: 25767098
[TBL] [Abstract][Full Text] [Related]
18. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
19. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]